The Global Iliac Stents Market was valued at USD 1 billion in 2025 and is estimated to grow at a CAGR of 4.7% to reach USD 1.6 billion by 2035.
Market expansion is driven by growing preference for minimally invasive procedures, advancements in stent materials and designs, and the increasing prevalence of peripheral artery disease (PAD). As populations age and risk factors such as diabetes, obesity, and smoking become more common, the incidence of PAD continues to climb, resulting in leg pain, cramping, and walking difficulties that affect quality of life. Clinical evidence demonstrating the long-term efficacy of stents, coupled with their expanding use in complex iliac lesions, is further fueling demand. The shift toward personalized vascular treatments has also amplified the adoption of iliac stents. These small, mesh-like devices, typically made from stainless steel or nitinol, are inserted into narrowed arteries to restore proper blood flow, improving patient outcomes while minimizing procedural risks compared to traditional open surgeries.
The common iliac artery lesions segment reached USD 639.6 million in 2025. Rising global risk factors such as hypertension, diabetes, and obesity accelerate atherosclerosis, increasing the number of patients requiring interventions. Minimally invasive techniques like angioplasty and stenting have revolutionized care for iliac artery lesions, driving adoption and demand.
The hospitals segment held a 56.8% share in 2025. These facilities are equipped with specialized units in interventional cardiology, vascular surgery, and radiology, staffed by skilled professionals capable of performing complex iliac stent procedures. Access to comprehensive resources, including medical supplies, medications, and support staff, positions hospitals as the primary end users for these devices.
U.S. Iliac Stents Market was valued at USD 225.2 million in 2025. Rising diabetes and obesity rates, coupled with increased R&D investments, are key growth drivers. Greater awareness among patients and healthcare providers has improved early diagnosis and intervention, while strong clinical evidence and guideline-backed recommendations for endovascular treatments reinforce the demand for iliac stents in the region.
Key players operating in the Global Iliac Stents Market include Medtronic, Boston Scientific, Abbott Laboratories, Biotronik, Becton, Dickinson and Company, Alvimedica, W. L. Gore & Associates, Inc., Cook, Cordis, iVascular, Getinge, and B. Braun. Companies in the Iliac Stents Market strengthen their position by focusing on research and development to create stents with enhanced flexibility, durability, and biocompatibility. Strategic partnerships with hospitals and healthcare providers expand product reach and adoption. Market penetration is supported by clinical trials that validate efficacy and safety, enhancing physician confidence. Firms also leverage regional expansions, regulatory approvals, and targeted educational programs for clinicians and patients to boost awareness. Additionally, collaborations with medical device distributors and the implementation of customized solutions for complex lesions help consolidate market share and maintain a competitive advantage.
This product will be delivered within 2-4 business days.
Market expansion is driven by growing preference for minimally invasive procedures, advancements in stent materials and designs, and the increasing prevalence of peripheral artery disease (PAD). As populations age and risk factors such as diabetes, obesity, and smoking become more common, the incidence of PAD continues to climb, resulting in leg pain, cramping, and walking difficulties that affect quality of life. Clinical evidence demonstrating the long-term efficacy of stents, coupled with their expanding use in complex iliac lesions, is further fueling demand. The shift toward personalized vascular treatments has also amplified the adoption of iliac stents. These small, mesh-like devices, typically made from stainless steel or nitinol, are inserted into narrowed arteries to restore proper blood flow, improving patient outcomes while minimizing procedural risks compared to traditional open surgeries.
The common iliac artery lesions segment reached USD 639.6 million in 2025. Rising global risk factors such as hypertension, diabetes, and obesity accelerate atherosclerosis, increasing the number of patients requiring interventions. Minimally invasive techniques like angioplasty and stenting have revolutionized care for iliac artery lesions, driving adoption and demand.
The hospitals segment held a 56.8% share in 2025. These facilities are equipped with specialized units in interventional cardiology, vascular surgery, and radiology, staffed by skilled professionals capable of performing complex iliac stent procedures. Access to comprehensive resources, including medical supplies, medications, and support staff, positions hospitals as the primary end users for these devices.
U.S. Iliac Stents Market was valued at USD 225.2 million in 2025. Rising diabetes and obesity rates, coupled with increased R&D investments, are key growth drivers. Greater awareness among patients and healthcare providers has improved early diagnosis and intervention, while strong clinical evidence and guideline-backed recommendations for endovascular treatments reinforce the demand for iliac stents in the region.
Key players operating in the Global Iliac Stents Market include Medtronic, Boston Scientific, Abbott Laboratories, Biotronik, Becton, Dickinson and Company, Alvimedica, W. L. Gore & Associates, Inc., Cook, Cordis, iVascular, Getinge, and B. Braun. Companies in the Iliac Stents Market strengthen their position by focusing on research and development to create stents with enhanced flexibility, durability, and biocompatibility. Strategic partnerships with hospitals and healthcare providers expand product reach and adoption. Market penetration is supported by clinical trials that validate efficacy and safety, enhancing physician confidence. Firms also leverage regional expansions, regulatory approvals, and targeted educational programs for clinicians and patients to boost awareness. Additionally, collaborations with medical device distributors and the implementation of customized solutions for complex lesions help consolidate market share and maintain a competitive advantage.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Research Methodology
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2025
Chapter 5 Market Estimates and Forecast, by Type, 2022-2035 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Artery Lesions, 2022-2035 ($ Mn)
Chapter 7 Market Estimates and Forecast, by End Use, 2022-2035 ($ Mn)
Chapter 8 Market Estimates and Forecast, by Region, 2022-2035 ($ Mn)
Chapter 9 Company Profiles
Companies Mentioned
The companies profiled in this Iliac Stents market report include:- Abbott Laboratories
- Alvimedica
- B. Braun
- Becton, Dickinson and Company
- Biotronik
- Boston Scientific
- Cook
- Cordis
- Getinge
- iVascular
- Medtronic
- W. L. Gore & Associates, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 135 |
| Published | March 2026 |
| Forecast Period | 2025 - 2035 |
| Estimated Market Value ( USD | $ 1 Billion |
| Forecasted Market Value ( USD | $ 1.6 Billion |
| Compound Annual Growth Rate | 4.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 13 |
